Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

View Full Paper
Ask AI
Bookmark
Share

Authors

FMFrancesco MannelliSSStefano SodduMVMarco Vignetti

Discussion

Loading...

Member takes

Overview

Randomized trial identifies key genetic mutations affecting survival in MPN-BP, suggesting that targeted therapies may improve outcomes.

Key Points

  • To define prognostic risk profiles associated with overall survival in patients with myeloproliferative neoplasm-blast phase treated with venetoclax and decitabine.
  • Phase 2 trial enrolled 101 patients with MPN-BP treated with venetoclax and decitabine.
  • DNA and mutations were analyzed using PCR assays and next-generation sequencing.
  • Karyotype abnormalities were classified following established criteria.
  • Karyotype and molecular information were evaluated in 80 patients; 90% had a driver mutation.
  • A 3-gene signature (SRSF2, U2AF1, TP53) predicted survival differences effectively, outperforming existing genetic risk models.
  • Overall survival rates varied significantly across risk categories, indicating the potential for improved prognostication.

Cite This Study

Mannelli et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d122https://doi.org/10.1182/blood-2025-3751
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax2025
  2. 2Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  3. 3Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial2025 · 4 citations
  4. 4Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study2025
  5. 5Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.2025